Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
- DOI
- 10.3389/fendo.2023.1165681
- Published
- 2023-10-09
- Container
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fendo.2023.1165681,
title = {Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease},
author = {Richard A. Feelders and Maria Fleseriu and Pinar Kadioglu and Marie Bex and Deyanira González-Devia and Cesar Luiz Boguszewski and Dilek Gogas Yavuz and Heather Patino and Alberto M. Pedroncelli and Ricardo Maamari and Arghya Chattopadhyay and Beverly M. K. Biller and Rosario Pivonello},
year = {2023},
journal = {Frontiers in Endocrinology},
doi = {10.3389/fendo.2023.1165681},
url = {https://doi.org/10.3389/fendo.2023.1165681}
}RIS
TY - JOUR TI - Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease AU - Richard A. Feelders AU - Maria Fleseriu AU - Pinar Kadioglu AU - Marie Bex AU - Deyanira González-Devia AU - Cesar Luiz Boguszewski AU - Dilek Gogas Yavuz AU - Heather Patino AU - Alberto M. Pedroncelli AU - Ricardo Maamari AU - Arghya Chattopadhyay AU - Beverly M. K. Biller AU - Rosario Pivonello PY - 2023 JO - Frontiers in Endocrinology DO - 10.3389/fendo.2023.1165681 UR - https://doi.org/10.3389/fendo.2023.1165681 ER -
APA
Feelders, R. A., Fleseriu, M., Kadioglu, P., Bex, M., González-Devia, D., Boguszewski, C. L., Yavuz, D. G., Patino, H., Pedroncelli, A. M., Maamari, R., Chattopadhyay, A., Biller, B. M. K., & Pivonello, R. (2023). Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2023.1165681
Source records
- crossref · retrieved 2026-09-26T05:44:57.533Z